Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Tests an exoskeleton walking device for leg weakness after stroke

Tests robotic exoskeleton-assisted walking training in adults recovering from stroke.

Plain-language title generated from the registry record
Registry title: Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke

Key facts

Where
Oklahoma City, United StatesSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

Source: NCT03980457, who can take part

Where in United States

  • Oklahoma City VA Health Care SystemOklahoma City, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Oklahoma
Trial code
NCT03980457
Record updated
1 April 2026
Original description
The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.Read full original descriptionShow less

Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke

The goal of this study is to determine the efficacy of electromechanical exoskeleton-assisted gait training on rehabilitation functional outcomes in patients with stroke undergoing therapy in an in-patient rehabilitation facility.

Inclusion: All patients with acute hemorrhagic or ischemic stroke documented clinically and by neuroimaging; Medically stable from a cardio-respiratory stand point so that they can participate in daily therapies; Depressed patients will be included in the study; Patients able to stand alone; Patients able to provide a written informed consent, from cognitively intact patients (admission Mini Mental Scale Examination [MMSE] greater than or equal to 21).

Exclusion: Aphasic patients unable to communicate; Confused patients; Patients medically unstable; Patients unable to stand alone; Refusal to provide written informed consent.

ClinicalTrials.gov NCT03980457